AbbVie (ABBV) Goodwill & Intangibles (2012 - 2026)
AbbVie (ABBV) reported Goodwill & Intangibles of $86.4 billion for Q1 2026, down 7.82% year-over-year from $93.8 billion in Q1 2025, and down 2.08% quarter-over-quarter from $88.3 billion in Q4 2025.
AbbVie (ABBV) Goodwill & Intangibles (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Goodwill & Intangibles data on file, last reported at $86.4 billion in Q1 2026.
- Goodwill & Intangibles for Q1 2026 came in at $86.4 billion, down 7.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.4 billion (down 7.82% YoY), and the FY2025 annual result was $88.3 billion, down 7.1% from the prior year.
- Goodwill & Intangibles fell to $86.4 billion in Q1 2026 per ABBV's latest filing, from $88.3 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $106.3 billion in Q1 2022 and troughed at $36.3 billion in Q3 2025.
- A 5-year average of $92.0 billion and a median of $95.0 billion in 2024 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2024 and 2025: Goodwill & Intangibles grew 12.4% in 2024, then slumped 64.35% in 2025.
- A 5-year view of Goodwill & Intangibles shows it stood at $99.6 billion in 2022, then slipped by 11.74% to $87.9 billion in 2023, then rose by 8.1% to $95.0 billion in 2024, then slipped by 7.1% to $88.3 billion in 2025, then declined by 2.08% to $86.4 billion in 2026.
- Business Quant data shows ABBV's Goodwill & Intangibles at $86.4 billion in Q1 2026, $88.3 billion in Q4 2025, and $36.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.44 Bn |
| Dec 31, 2025 | 88.28 Bn |
| Sep 30, 2025 | 36.34 Bn |
| Jun 30, 2025 | 92.67 Bn |
| Mar 31, 2025 | 93.77 Bn |
| Dec 31, 2024 | 95.02 Bn |
| Sep 30, 2024 | 101.94 Bn |
| Jun 30, 2024 | 93.63 Bn |
| Mar 31, 2024 | 95.65 Bn |
| Dec 31, 2023 | 87.90 Bn |
| Sep 30, 2023 | 90.69 Bn |
| Jun 30, 2023 | 95.09 Bn |
| Mar 31, 2023 | 97.07 Bn |
| Dec 31, 2022 | 99.60 Bn |
| Sep 30, 2022 | 100.45 Bn |
| Jun 30, 2022 | 103.85 Bn |
| Mar 31, 2022 | 106.28 Bn |
| Dec 31, 2021 | 108.33 Bn |
| Sep 30, 2021 | 109.75 Bn |
| Jun 30, 2021 | 111.74 Bn |